Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu BioPharma, Inc. - Common Stock (NQ: AYTU )

1.500 UNCHANGED
Streaming Delayed Price Updated: 12:59 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Aytu BioPharma to Participate in the 34th Annual Roth Conference
ENGLEWOOD, CO / ACCESSWIRE / March 8, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Mark Oki,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Closing of $7.6 Million Registered Offering
ENGLEWOOD, CO / ACCESSWIRE / March 7, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces Pricing of $7.6 Million Registered Offering
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the placement to... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European... 
From Aytu BioPharma, Inc.
Via AccessWire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Soleno Therapeutics (NASDAQ:SLNO) shares rose 15.7% to $0.37 during Monday's pre-market session. The market value of their outstanding shares is at $29.5... 
Via Benzinga
Aytu BioScience's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q2, Aytu BioScience's (NASDAQ:AYTU) reported sales totaled $23.12 million. Despite a 58.54% increase in earnings, the company posted a loss of $11.55... 
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
Aytu BioPharma Announces Business and Pipeline Progress and Reports Second Quarter 2022 Financial Results
Quarterly Net Revenue Increased 53% Year-over-year to $23.1 Million PREVEnt Pivotal Study for AR101 in Vascular Ehlers-Danlos Syndrome On-track to Begin in Mid-2022 Initiation of Randomized,... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioScience, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 01/31/2022 -- An investigation was announced on behalf of investors of Aytu BioScience, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu... 
Via SBWire
Aytu BioPharma Completes $15 Million Debt Refinancing
ENGLEWOOD, CO / ACCESSWIRE / January 31, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that it has... 
From Aytu BioPharma, Inc.
Via AccessWire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Enveric Biosciences (NASDAQ:ENVB)... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Acorda Therapeutics (NASDAQ:ACOR)... 
Via Benzinga
Aytu BioPharma Appoints Mark Oki as Chief Financial Officer
ENGLEWOOD, CO / ACCESSWIRE / January 4, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today... 
From Aytu BioPharma, Inc.
Via AccessWire
Aytu BioPharma to Present at H.C. Wainwright BioConnect Conference
ENGLEWOOD, CO / ACCESSWIRE / January 3, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today... 
From Aytu BioPharma, Inc.
Via AccessWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Star Equity Hldgs (NASDAQ:STRR) s... 
Via Benzinga
Investigation Announced for Investors in NASDAQ:AYTU Shares of Possible Violations of Securities Laws by Aytu BioScience, Inc
San Diego, CA -- (SBWIRE) -- 12/14/2021 -- Aytu BioScience, Inc is under investigation concerning potential securities laws violations in connection with certain financial statements. 
Via SBWire
Aytu BioPharma Announces FDA Clearance of Investigational New Drug (IND) Application for AR101/Enzastaurin in Vascular Ehlers-Danlos Syndrome
Pivotal clinical trial will begin in first half of 2022 ENGLEWOOD, CO / ACCESSWIRE / December 13, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Aytu BioPharma Receives Orphan Drug Designation from FDA for AR101 for Treatment of Vascular Ehlers-Danlos Syndrome
ENGLEWOOD, CO / ACCESSWIRE / December 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Product Safety Regulatory
Aytu BioScience, Inc. (NASDAQ: AYTU) Shareholder Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 11/30/2021 -- Certain directors of Aytu BioScience, Inc are under investigation on over potential breaches of fiduciary dutie. 
Via SBWire
Aytu BioPharma Announces Issuance of First U.S. Patent Supporting Healight Ultraviolet-A Respiratory Catheter
ENGLEWOOD, CO / ACCESSWIRE / November 23, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 50(TM)
ENGLEWOOD, CO / ACCESSWIRE / November 17, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Aytu BioPharma Reports First Quarter 2022 Financial Results
Quarterly net revenue increased 62% to $21.9 million Ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash Fully integrated and expanding RxConnect patient... 
From Aytu BioPharma, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Aytu BioPharma, Inc. (NASDAQ:AYTU) Investor Alert: Investigation over Possible Violations of Securities Laws
San Diego, CA -- (SBWIRE) -- 11/09/2021 -- An investigation was announced for investors of Aytu BioPharma, Inc. (NASDAQ:AYTU) shares over potential securities laws violations by Aytu BioPharma, Inc.... 
Via SBWire
Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021
ENGLEWOOD, CO / ACCESSWIRE / November 8, 2021 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products,... 
From Aytu BioPharma, Inc.
Via AccessWire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
CORRECTION: Aytu BioPharma to Present at Upcoming September Investor Conferences
(This release corrects the previous one that was issued on September 7, 2021 to reflect the time of the Cantor Presentation being changed to 2:40 pm EST) ENGLEWOOD, CO / ACCESSWIRE / September 30, 2021... 
From Aytu BioPharma, Inc.
Via AccessWire
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.